Patient info Open main menu

Aivlosin - patient leaflet, side effects, dosage

Contains active substance:

Dostupné balení:

Patient leaflet - Aivlosin

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

Aivlosin 42.5 mg/g premix for medicated feeding stuff for pigs

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Manufacturer responsible for batch release:

Acme Drugs s.r.l.

Via Portella della Ginestra 9/a

42025 CAVRIAGO (RE)

ITALY

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Aivlosin 42.5 mg/g premix for medicated feeding stuff for pigs Tylvalosin (as tylvalosin tartrate)

3.


STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Active substance:

Tylvalosin (as tylvalosin tartrate) 42.5 mg/g.

A beige granular powder.

Carrier:

Hydrated magnesium silicate, wheat flour.

  • 4. INDICATIONS

  • Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae. At the recommended dose, lung lesions and weight loss are reduced but infection with Mycoplasma hyopneumoniae is not eliminated.
  • Treatment of porcine proliferative enteropathy (ileitis) caused by Lawsonia intracellularis in

herds where there is a diagnosis based on clinical history, post-mortem findings and clinical pathology results.

Treatment and metaphylaxis of swine dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed.

  • 5. CONTRAINDI­CATIONS

None.

  • 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Pigs.

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

In-feed use.

For incorporation into dry feed only.

For treatment and metaphylaxis of swine enzootic pneumonia:

The dose is 2.125 mg tylvalosin per kg bodyweight per day in-feed for 7 consecutive days. Secondary infection by organisms such as Pasteurella multocida and Actinobacillus pleuropneumoniae may complicate enzootic pneumonia and require specific medication.

For treatment of porcine proliferative enteropathy (ileitis):

The dose is 4.25 mg tylvalosin per kg bodyweight per day in-feed for 10 consecutive da­ys.

For treatment and metaphylaxis of swine dysentery:

The dose is 4.25 mg tylvalosin per kg bodyweight per day in-feed for 10 consecutive da­ys.

Indication

Dose of active ingredient

Duration of treatment

In feed inclusion rate

Treatment and metaphylaxis of swine enzootic pneumonia

2.125 mg/kg bodyweight/day

7 days

1 kg/tonne*

Treatment of PPE (ileitis)

4.25 mg/kg bodyweight/day

10 days

2 kg/tonne*

Treatment and metaphylaxis of swine dysentery

4.25 mg/kg bodyweight/day

10 days

2 kg/tonne

Important : these inclusion rates assume a pig eats the equivalent of 5% bodyweight per day.

In older pigs, or in pigs with reduced appetite, or on restricted feed intake, inclusion levels may need to be increased to achieve target dose. Where feed intake is reduced, use the following formula:

Kg premix/tonne feed


Dose rate (mg/kg bodyweight) x bodyweight (kg) Daily feed intake (kg) x Premix strength (mg/g)

Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product.

In addition to medical treatment, good management and hygiene practices should be established on the farm in order to reduce the risk of infection and to control the build-up of resistance.

The medicated feed should be fed as the sole ration.

  • 9. ADVICE ON CORRECT ADMINISTRATION

Mixing instructions

A horizontal ribbon mixer should be used to incorporate the veterinary medicinal product into feeding stuff. It is recommended that Aivlosin is first mixed with 10 kg of the feeding stuff, followed by the rest of the feeding stuff and mixed well. Medicated feed may then be pelleted. Pelleting conditions involve a single pre-conditioning step with steam for 5 minutes and pelleting at not more than 70 °C under normal conditions.

  • 10. WITHDRAWAL PERIOD(S)

Meat and offal: 2 days.

  • 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store below 30 °C.

Keep the container tightly closed.

Store in the original container.

Shelf life after first opening the immediate packaging: use immediately. Opened bags should not be stored.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after “EXP”.

Shelf life after incorporation into feed: meal and pellets: 1 month.

  • 12. SPECIAL WARNINGS

Special warnings for each target species:

Acute cases and severely diseased pigs with reduced food or water intake should be treated with a suitable injectable product.

Generally, strains of B. hyodysenteriae have higher minimal inhibitory concentration (MIC) values in cases of resistance against other macrolides, such as tylosin. The clinical relevance of this reduced susceptibility is not fully explored. Cross-resistance between tylvalosin and other macrolides cannot be excluded.

Special precautions for use in animals:

Good management and hygiene practices should be followed to reduce the risk of re-infection.

It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.

Use of the veterinary medicinal product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin should avoid contact with this product.

When mixing the veterinary medicinal product and handling the medicated premix, direct contact with eyes, skin and mucous membranes should be avoided. Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a nondisposable respirator conforming to European Standard EN 140 with a filter conforming to European Standard EN 143 should be worn when mixing the product. Wash contaminated skin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of Aivlosin during pregnancy and lactation has not been established in pigs. Use only in accordance with benefit-risk assessment by the responsible veterinarian. Laboratory studies in animals have not produced any evidence of a teratogenic effect. Maternal toxicity in rodents has been observed at doses of 400 mg tylvalosin per kg bodyweight and above. In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.

Overdose (symptoms, emergency procedures, antidotes) :

No signs of intolerance have been observed in growing pigs at up to 10 times the recommended dose.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency.

  • 15. OTHER INFORMATION

Available in pack sizes containing 5 kg or 20 kg of product.

Not all pack sizes may be marketed. Consideration should be given to official guidance on the incorporation of medicated premixes in final feed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Belgie/Belgiqu­e/Belgien

Ecuphar NV/SA

Legeweg 157-I,

BE-8020 Oostkamp

Tel: +32 50 31 42 69

Fax: +32 50 36 24 17

Email:

Luxembourg/Lu­xemburg

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Penyß^uKa Et.nrapun

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

me.iec])OH: +44 (0) 20 8447 8899

Email:

Magyarorszag

Dunavet-B ZRt, 7020 Dunafôldvâr, Ady E. u. 5. Tel: +36 75 542 940

Email:

Česká republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno

Tel: +42 (0) 54 1426 370

Email:

Malta

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Danmark

Salfarm Danmark A/S

Fabriksvej 21 6000 Kolding

Tel: +45 75 52 94 13

Fax: +45 75 50 80 80

E-mail:

Nederland

Ecuphar BV

Verlengde Poolseweg 16

NL-4818 CL Breda

Tel : +31 (0)88 033 38 00

Fax : +31 (0)88 033 38 11

Email:

Deutschland

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 3584 0

Norge

Salfarm Scandinavia AB Florettgatan 29C, 2. Vân 25 467 Helsingborg

Sweden

Phone: 0046 767 834 910

Fax: 0045 7550 8080

Email:

Eesti

AS Magnum Veterinaaria Vae 16, Laagri, Harju mk Tel: +372 6 501 920

Fax: +372 6 501 996

Österreich

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 3584 0

EXXàôa

DG Nucleus EnE

N.XapÍTOU 11 43100 Kapôiroa

Tql:+302441073034

Email:

Polska

Calier Polska Sp. z o.o. ul. Magazynowa 5, 66–446 Deszczno

Tel: +48 95 7214521 fax: +48 95 7214532

E-mail:

HURTOWNIA LEKOW

WETERYNARYJNYCH „AGA-VET“ ul. Turkowska 58c

62–720 Brudzew

Tel: +48 (63) 279 70 04

Email:

España

Ecuphar Veterinaria S.L.U. Avenida Río de Janeiro, 60–66, planta 13 08016 Barcelona

Tel: +34 (0)935 955 000

Portugal

Belphar LDA

Sintra Business Park No 7, Edificio 1– Escritorio 2K Zona Industrial de Abrunheira 2710–089 Sintra

Tel: +35 (0)13088 08321

France

Laboratoire LCV Z.I. Plessis Beucher 35220 Châteaubourg

Tél : +33 (0)2 99 00 92 92

Fax : +33 (0)2 99 00 97 23

Romania

SC MARAVET SA

Baia Mare

Maravet,

Street No 1

Tel: +40 262 211 964

Email :

Ireland

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenija

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Island

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenská republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno Česká Republika

Tel: +42 (0) 54 1426 370

Email:

Italia

Ecuphar Italia S.R.L.

Viale Francesco Restelli, 3/7, piano 1 20124

Milano

Tel: +39 (0)02829 50604

Suomi/Finland

Vetcare Oy

PL 99

24101 Salo

Tel: +358 (0)20 144 3360

Email:

Knnpog

Panchris Feeds (Veterinary) Ltd

Industrial Area Aradippou, 7100, Larnaca,

POB 40261, 6302, Larnaca,

Tql: + 357 24813333

Fax: +357 24813377

Sverige

Salfarm Scandinavia AB Florettgatan 29C, 2. Ván 25 467 Helsingborg Phone: 0046 767 834 9­10 Fax: 0045 7550 808­0 Email:

Latvija

Magnum Veterinarija SIA Ulbrokas iela 23, Riga, LV-1021, Tel: +371 671 60091

Fax: +371 671 60095

Lietuva

Magnum Veterinarija, UAB

Martinavos g. 8, Martinavos k.,

LT-54463 Kauno r., Lietuva

Tel.: +370 688 96944

Email:

PACKAGE LEAFLET:

Aivlosin 625 mg/g granules for use in drinking water for pigs

(attached as concertina label directly to the immediate package or as a back label for the 400 g sachet for one language)

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Manufacturer responsible for batch release :

Acme Drugs s.r.l.

Via Portella della Ginestra 9/a

42025 CAVRIAGO (RE)

ITALY

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Aivlosin 625 mg/g granules for use in drinking water for pigs

Tylvalosin (as tylvalosin tartrate)

  • 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT

Active substance:

Tylvalosin (as tylvalosin tartrate) 625 mg/g.

White granules.

  • 4. INDICATION(S)

Treatment and metaphylaxis of porcine proliferative enteropathy (ileitis) caused by Lawsonia intracellularis.

Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae.

The presence of the disease in the group must be established before metaphylaxis.

  • 5. CONTRAINDI­CATIONS

None.

  • 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Pigs.

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For use in drinking water.

To ensure a correct dosage, bodyweight should be determined as accurately as possible. Water consumption should be monitored, and the concentration of the product adjusted if needed to avoid underdosing.

The product should be added to a volume of water that the pigs will consume in one day. No other source of drinking water should be available during treatment.

Porcine proliferative enteropathy (ileitis) caused by Lawsonia intracellularis

The dose is 5 mg tylvalosin per kg bodyweight per day in drinking water for 5 consecutive days.

Calculate the total amount of product required with the formula:

Total weight of product in grams = total bodyweight of the heaviest pig to be treated in kg x number of pigs x 5 / 625.

Select the correct number and size of sachets according to the amount of product required.

The 40 g sachet is sufficient to treat a total of 5,000 kg of pigs (e.g. 250 pigs with the heaviest pig weighing 20 kg) for one day.

The 160 g sachet is sufficient to treat a total of 20,000 kg of pigs (e.g. 400 pigs with the heaviest pig weighing 50 kg) for one day.

The 400 g sachet is sufficient to treat a total of 50,000 kg of pigs (e.g. 1000 pigs with the heaviest pig weighing 50 kg) for one day.

Swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae

The dose is 10 mg tylvalosin per kg bodyweight per day in drinking water for 5 consecutive days.

Calculate the total amount of product required with the following formula:

Total weight of product in grams = total bodyweight of the heaviest pig to be treated in kg x number of pigs to be treated x 10 / 625.

Select the correct number of sachets according to the amount of product required.

The 40 g sachet is sufficient to treat a total of 2,500 kg of pigs (e.g. 125 pigs with the heaviest pig weighing 20 kg) for one day.

The 160 g sachet is sufficient to treat a total of 10,000 kg of pigs (e.g. 200 pigs with the heaviest pig weighing 50 kg) for one day.

The 400 g sachet is sufficient to treat a total of 25,000 kg of pigs (e.g. 500 pigs with the heaviest pig weighing 50 kg) for one day.

  • 9. ADVICE ON CORRECT ADMINISTRATION

In order to achieve a correct dose, accurate and properly calibrated equipment should be used for weighing out the required amount of product.

The veterinary medicinal product may be mixed directly into the drinking water system or first mixed as a stock solution into a smaller amount of water, which is then added into the drinking water system.

When mixing the product directly into the drinking water system, the contents of the sachet should be sprinkled onto the surface of the water and mixed thoroughly until a clear solution is produced (usually within 3 minutes).

When preparing a stock solution, the maximum concentration should be 40 g of product per 1,500 ml, 160 g of product per 6,000 ml or 400g of product per 15,000 ml water and it is necessary to mix the solution for 10 minutes. After this time, any remaining cloudiness will not affect the efficacy of the veterinary medicinal product.

Only a sufficient amount of medicated drinking water should be prepared to cover the daily requirements.

Medicated drinking water should be replaced every 24 hours.

After end of the medication period, the water supply system should be cleaned appropriately to avoid intake of subtherapeutic amounts of the active substance.

As an adjunct to medication, good management and hygiene practices should be introduced in order to reduce the risk of infection and to control the build-up of resistance.

  • 10. WITHDRAWAL PERIOD(S)

Meat and offal: 2 days.

11.


SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

40 g sachet: do not store above 25 °C.

160 g sachet: do not store above 25 °C.

400 g sachet: do not store above 25 °C.

Shelf life after opening the immediate packaging: 5 weeks.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after “EXP”.

Shelf life of the medicated drinking water: 24 hours.

  • 12. SPECIAL WARNINGS

Special warnings for each target species:

In severely diseased pigs, if water intake is reduced, pigs should be treated with a suitable injectable veterinary medicinal product prescribed by a veterinarian.

At the recommended dose, lung lesions and clinical signs are reduced but infection with Mycoplasma hyopneumoniae is not eliminated.

Special precautions for use in animals:

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Good management and hygiene practices should be followed to reduce the risk of re-infection.

It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.

Use of the veterinary medicinal product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance.

An antibacterial with a lower risk of antimicrobial resistance selection, if available for the same indication, should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

Special precautions to be taken by the person administering the veterinary medicinal product to animals :

Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin should avoid contact with this product.

When mixing the veterinary medicinal product and handling the medicated water, direct contact with eyes, skin and mucous membranes should be avoided. Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a nondisposable respirator conforming to European Standard EN 140 with a filter conforming to European Standard EN 143 should be worn when mixing the product. Wash contaminated skin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in pigs. Use only in accordance with benefit-risk assessment by the responsible veterinarian.

Laboratory studies in animals have not produced any evidence of a teratogenic effect. Maternal toxicity in rodents has been observed at doses of 400 mg tylvalosin per kg bodyweight and above. In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.

Overdose (symptoms, emergency procedures, antidotes) :

No signs of intolerance have been observed in pigs at up to 100 mg tylvalosin per kg bodyweight per day for 5 days.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE

MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency.

15.


OTHER INFORMATION


Available in sachets containing 40 g, 160 g or 400 g of granules. Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Belgie/Belgiqu­e/Belgien

Vaccifar BVBA Sint Damiaanstraat 18 B-2160 Wommelgem BELGIUM

Tel : +32 3 355 29 50

Email :

Luxembourg/Lu­xemburg

Vaccifar BVBA Sint Damiaanstraat 18

B-2160 Wommelgem

BELGIUM

Tel : +32 3 355 29 50

Email :

PenySnuKa EBnrapun

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

me.iec])OH: +44 (0) 20 8447 8899

Email:

Magyarorszag

Dunavet-B ZRt, 7020 Dunafoldvar, Ady E. u. 5. Tel: +36 75 542 940

Email:

Česká republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno

Tel: +42 (0) 54 1426 370

Email:

Malta

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Danmark

Salfarm Danmark A/S

Fabriksvej 21 6000 Kolding

Tel: +45 75 52 94 13

Fax: +45 75 50 80 80

E-mail:

Nederland

Vaccifar BVBA Sint Damiaanstraat 18 B-2160 Wommelgem BELGIUM

Tel : +32 3 355 29 50

Email :

Deutschland

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

Norge

Salfarm Scandinavia AB Florettgatan 29C, 2. Van 25 467 Helsingborg

Sweden

Phone: 0046 767 834 910

Fax: 0045 7550 8080

Email:

Eesti

AS Magnum Veterinaaria

Vae 16, Laagri, Harju mk

Tel: +372 6 501 920

Fax: +372 6 501 996

Österreich

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

EZZáSa

DG Nucleus EnE

N.XapÍTOU 11 43100 KapSwoa Tql:+30244107­3034 Email:

Polska

Calier Polska Sp. z o.o. ul. Magazynowa 5, 66–446 Deszczno

Tel: +48 95 7214521 fax: +48 95 7214532

E-mail:.pl

HURTOWNIA LEKOW

WETERYNARYJNYCH „AGA-VET“ ul. Turkowska 58c

62–720 Brudzew

Tel: +48 (63) 279 70 04

Email:

España

Ecuphar Veterinaria S.L.U. Avenida Río de Janeiro, 60–66, planta 13 08016 Barcelona

Tel: +34 (0)935 955 000

Portugal

Belphar LDA

Sintra Business Park No 7, Edificio 1– Escritorio 2K Zona Industrial de Abrunheira 2710–089 Sintra

Tel: +35 (0)13088 08321

France

Laboratoire LCV Z.I. Plessis Beucher 35220 Châteaubourg

Tél : +33 (0)2 99 00 92 92

Fax : +33 (0)2 99 00 97 23

Romania

SC MARAVET SA

Baia Mare

Maravet,

Street No 1

Tel: +40 262 211 964

Email :

Ireland

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenija

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Island

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenská republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno Česká Republika

Tel: +42 (0) 54 1426 370

Email:

Italia

Ecuphar Italia S.R.L.

Viale Francesco Restelli, 3/7, piano 1 20124

Milano

Tel: +39 (0)02829 50604

Suomi/Finland

Vetcare Oy

PL 99

24101 Salo

Tel: +358 (0)20 144 3360

Email:

Knnpoç

Panchris Feeds (Veterinary) Ltd

Industrial Area Aradippou, 7100, Larnaca,

POB 40261, 6302, Larnaca,

Tql: + 357 24813333

Fax: +357 24813377

Sverige

Salfarm Scandinavia AB Florettgatan 29C, 2. Ván 25 467 Helsingborg Phone: 0046 767 834 9­10 Fax: 0045 7550 808­0 Email:

Latvija

Magnum Veterinarija SIA

Ulbrokas iela 23, Riga, LV-1021,

Tel: +371 671 60091

Fax: +371 671 60095

Lietuva

Magnum Veterinarija, UAB

Martinavos g. 8, Martinavos k.,

LT-54463 Kauno r., Lietuva

Tel.: +370 688 96944

Email:

PACKAGE LEAFLET:

Aivlosin 625 mg/g granules for use in drinking water for pheasants

(attached as concertina label directly to the immediate package or as a back label for the 400 g sachet for one language)

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Manufacturer responsible for batch release :

Acme Drugs s.r.l.

Via Portella della Ginestra 9/a

42025 CAVRIAGO (RE)

ITALY

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Aivlosin 625 mg/g granules for use in drinking water for pheasants

Tylvalosin (as tylvalosin tartrate)

  • 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT

Active substance:

Tylvalosin (as tylvalosin tartrate) 625 mg/g.

White granules.

  • 4. INDICATION(S)

Treatment of respiratory disease associated with Mycoplasma gallisepticum in pheasants.

  • 5. CONTRAINDI­CATIONS

None.

  • 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Pheasants.

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For use in drinking water.

The dose is 25 mg tylvalosin per kg bodyweight per day in drinking water for 3 consecutive days.

Determine the combined bodyweight (in kg) of all the birds to be treated. For example, one sachet of 40 g is sufficient to treat a total of 1,000 birds with an average bodyweight of 1 kg; one sachet of 400 g is sufficient to treat a total of 10,000 birds with an average bodyweight of 1kg.

In order to achieve a correct dose, the preparation of a concentrated (stock) solution might be required (e.g. to treat a total of 500 kg total bird weight, only 50% of the prepared stock solution prepared from the 40 g sachet should be used).

The veterinary medicinal product should be added to a volume of water that the birds will consume in one day. No other source of drinking water should be available during the medication period.

  • 9. ADVICE ON CORRECT ADMINISTRATION

The veterinary medicinal product may be mixed directly into the drinking water system or first mixed as a stock solution into a smaller amount of water, which is then added into the drinking water system.

When mixing the veterinary medicinal product directly into the drinking water system, the contents of the sachet should be sprinkled onto the surface of the water and mixed thoroughly until a clear solution is produced (usually within 3 minutes).

When preparing a stock solution, the maximum concentration should be 40 g of product per 1,500 ml of water and it is necessary to mix the solution for 10 minutes. After this time, any remaining cloudiness will not affect efficacy of the veterinary medicinal product.

Only a sufficient amount of medicated drinking water should be prepared to cover the daily requirements.

Medicated drinking water should be replaced every 24 hours.

  • 10. WITHDRAWAL PERIOD(S)

Meat and offal: 2 days.

Do not release pheasants for at least two days after the end of medication.

Not for use in birds producing or intended to produce eggs for human consumption.

Do not use within 14 days of the start of the laying period.

  • 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

40 g sachet: do not store above 25 °C.

400 g sachet: do not store above 25 °C.

Shelf life after opening the immediate packaging: 5 weeks.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after “EXP”.

Shelf life of the medicated drinking water: 24 hours.

  • 12. SPECIAL WARNINGS

Special warning for each target species:

Treat as soon as possible after clinical signs suggestive of mycoplasmosis are observed.

Treat all the birds in the affected flock.

Special precautions for use in animals:

Good management and hygiene practices should be introduced in order to reduce the risk of reinfection.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin should avoid contact with this product.

When mixing the veterinary medicinal product and handling the medicated water, direct contact with eyes, skin and mucous membranes should be avoided. Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a nondisposable respirator conforming to European Standard EN 140 with a filter conforming to European Standard EN 143 should be worn when mixing the product. Wash contaminated skin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Lay:

Use only in accordance with benefit-risk assessment by the responsible veterinarian.

Overdose (symptoms, emergency procedures, antidotes) :

No signs of intolerance have been observed in poultry species at up to 150 mg tylvalosin per kg bodyweight per day for 5 days.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency.

  • 15. OTHER INFORMATION

Available in sachets containing 40 g or 400 g of product. Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgiqu­e/Belgien

Ecuphar NV/SA

Legeweg 157-I,

BE-8020 Oostkamp

Tel: +32 50 31 42 69

Fax: +32 50 36 24 17

Email:

Luxembourg/Lu­xemburg

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Peny6^uKa Et^rapun

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

mene^OH: +44 (0) 20 8447 8899

Email:

Magyarorszag

Dunavet-B ZRt, 7020 Dunafoldvâr, Ady E. u. 5. Tel: +36 75 542 940

Email:

Česká republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno

Tel: +42 (0) 54 1426 370

Email:

Malta

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Danmark

Salfarm Danmark A/S

Fabriksvej 21 6000 Kolding

Tel: +45 75 52 94 13

Fax: +45 75 50 80 80

E-mail:

Nederland

Ecuphar BV

Verlengde Poolseweg 16

NL-4818 CL Breda

Tel : +31 (0)88 033 38 00

Fax : +31 (0)88 033 38 11

Email:

Deutschland

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

Norge

Salfarm Scandinavia AB Florettgatan 29C, 2. Van 25 467 Helsingborg

Sweden

Phone: 0046 767 834 910

Fax: 0045 7550 8080

Email:

Eesti

AS Magnum Veterinaaria

Vae 16, Laagri, Harju mk

Tel: +372 6 501 920

Fax: +372 6 501 996

Österreich

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

EZZaöa

DG Nucleus EnE N.XapÍTOU 11 43100 Kapöiioa Tql:+30244107­3034 Email:

Polska

Calier Polska Sp. z o.o. ul. Magazynowa 5, 66–446 Deszczno

Tel: +48 95 7214521 fax: +48 95 7214532

E-mail:

HURTOWNIA LEKOW

WETERYNARYJNYCH „AGA-VET“ ul. Turkowska 58c

62–720 Brudzew

Tel: +48 (63) 279 70 04

Email:

España

Ecuphar Veterinaria S.L.U. Avenida Río de Janeiro, 60–66, planta 13 08016 Barcelona

Tel: +34 (0)935 955 000

Portugal

Belphar LDA

Sintra Business Park No 7, Edificio 1– Escritorio 2K Zona Industrial de Abrunheira 2710–089 Sintra

Tel: +35 (0)13088 08321

France

Laboratoire LCV Z.I. Plessis Beucher 35220 Châteaubourg

Tél : +33 (0)2 99 00 92 92

Fax : +33 (0)2 99 00 97 23

Romania

SC MARAVET SA

Baia Mare

Maravet,

Street No 1

Tel: +40 262 211 964

Email :

Ireland

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenija

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Island

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenská republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno Česká Republika

Tel: +42 (0) 54 1426 370

Email:

Italia

Ecuphar Italia S.R.L.

Viale Francesco Restelli, 3/7, piano 1 20124

Milano

Tel: +39 (0)02829 50604

Suomi/Finland

Vetcare Oy

PL 99

24101 Salo

Tel: +358 (0)20 144 3360

Email:

Knnpoç

Panchris Feeds (Veterinary) Ltd

Industrial Area Aradippou, 7100, Larnaca,

POB 40261, 6302, Larnaca

Tql: + 357 24813333

Fax: +357 24813377

Sverige

Salfarm Scandinavia AB Florettgatan 29C, 2. Ván 25 467 Helsingborg Phone: 0046 767 834 9­10 Fax: 0045 7550 808­0 Email:

Latvija

Magnum Veterinarija SIA

Ulbrokas iela 23, Riga, LV-1021,

Tel: +371 671 60091

Fax: +371 671 60095

Lietuva

Magnum Veterinarija, UAB

Martinavos g. 8, Martinavos k.,

LT-54463 Kauno r., Lietuva

Tel.: +370 688 96944

Email:

PACKAGE LEAFLET:

Aivlosin 42.5 mg/g oral powder for pigs

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Manufacturer responsible for batch release:

Acme Drugs s.r.l.

Via Portella della Ginestra 9/a

42025 CAVRIAGO (RE)

ITALY

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Aivlosin 42.5 mg/g oral powder for pigs

Tylvalosin (as tylvalosin tartrate)

  • 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Active substance:

Tylvalosin 42.5 mg/g.

(as tylvalosin tartrate)

A beige granular powder

4.


INDICATION(S)


Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae. At the recommended dose, lung lesions and weight loss are reduced but infection with Mycoplasma hyopneumoniae is not eliminated.

Treatment of porcine proliferative enteropathy caused by Lawsonia intracellularis.

Treatment and metaphylaxis of swine dysentery in herds, where the disease has been diagnosed.

5.


CONTRAINDICATIONS


None.

  • 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Pigs.

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For oral use.

The oral powder is for use in individual pigs on farms where only a small number of pigs are to receive the treatment. Larger groups should be treated with medicated feeding stuff containing the premix.

For treatment and metaphylaxis of swine enzootic pneumonia

The dose is 2.125 mg tylvalosin per kg bodyweight per day in-feed for 7 consecutive days.

Secondary infection by organisms such as Pasteurella multocida and Actinobacillus pleuropneumoniae may complicate enzootic pneumonia and require specific medication.

For treatment of porcine proliferative enteropathy (ileitis)

The dose is 4.25 mg tylvalosin per kg bodyweight per day for 10 consecutive da­ys.

For treatment and metaphylaxis of swine dysentery

The dose is 4.25 mg tylvalosin per kg bodyweight per day for 10 consecutive da­ys.

  • 9. ADVICE ON CORRECT ADMINISTRATION

This is achieved by thoroughly mixing Aivlosin into approximately 200–500 g of feed and then thoroughly mixing this pre-mixture into the remainder of the daily ration.

Scoops of 2 sizes are provided for measuring the correct amount of Aivlosin for mixing with the daily ration, according to the schedule below. The feed containing the oral powder should be provided as the sole ration for the periods recommended above.

The pig to be treated should be weighed and the amount of feed that the pig is likely to consume should be estimated, based on a daily feed intake equivalent to 5% of bodyweight. Consideration must be given to pigs whose daily feed intake is reduced or restricted. The correct quantity of Aivlosin 42.5 mg/g oral powder should then be added to the estimated quantity of daily ration for each pig, in a bucket or similar receptacle, and thoroughly mixed.

The veterinary medicinal product should only be added to dry non-pelleted feed.

Swine enzootic pneumonia

2.125 mg/kg bodyweight

Bodyweight range (kg)

Scoop size

Number of scoops

7.5–12

1 ml

1

13–25

1 ml

2

26–38

1 ml

3

39–67

5 ml

1

68–134

5 ml

2

135–200

5 ml

3

201–268

5 ml

4


PPE (ileitis) and swine dysentery

4.25 m.g/kg bodyweight

Bodyweight range(kg)

Scoop size

Number of scoops

7.5–12

1 ml

2

13–19

1 ml

3

20–33

5 ml

1

34–67

5 ml

2

68–100

5 ml

3

101–134

5 ml

4

135–200

5 ml

6

201–268

5 ml

8


NB: A level scoop of the product should be measured.

Acute cases and severely diseased pigs with reduced food or water intake should be treated with a suitable injectable veterinary medicinal product.

In addition to medical treatment, good management and hygiene practices should be established on the farm in order to reduce the risk of infection and to control the potential development of resistance.

  • 10. WITHDRAWAL PERIOD(S)

Meat and offal: 2 days.

  • 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store below 30 °C.

Keep the container tightly closed.

Store in the original container.

Shelf life after opening the immediate packaging: 4 weeks.

Do not use this veterinary medicinal product after the expiry date stated on the label after “EXP”.

Feed to which the oral powder has been added should be replaced if not consumed within 24 hours.

  • 12. SPECIAL WARNINGS

Special warnings for each target species:

Acute cases and severely diseased pigs with reduced food or water intake should be treated with a suitable injectable product.

Generally, strains of B. hyodysenteriae have higher minimal inhibitory concentration (MIC) values in cases of resistance against other macrolides, such as tylosin. The clinical relevance of this reduced susceptibility is not fully explored.

Cross-resistance between tylvalosin and other macrolides cannot be excluded.

Special precautions for use in animals:

It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.

Use of the veterinary medicinal product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance.

Good management and hygiene practices should be followed to reduce the risk of re-infection.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin should avoid contact with this product.

When mixing the veterinary medicinal product and handling the medicated oral powder, direct contact with eyes, skin and mucous membranes should be avoided. Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a nondisposable respirator conforming to European Standard EN 140 with a filter conforming to European Standard EN 143 should be worn when mixing the product. Wash contaminated skin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of Aivlosin during pregnancy and lactation has not been established in pigs. Use only in accordance with benefit-risk assessment by the responsible veterinarian. Laboratory studies in animals have not produced any evidence of a teratogenic effect. Maternal toxicity in rodents has been observed at doses of 400 mg tylvalosin per kg bodyweight and above. In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.

Overdose (symptoms, emergency procedures, antidotes) :

No signs of intolerance have been observed in growing pigs at up to 10 times the recommended dose.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency.

  • 15. OTHER INFORMATION

Available in a sachet containing 500 g of product.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgiqu­e/Belgien

Ecuphar NV/SA

Legeweg 157-I,

BE-8020 Oostkamp

Tel: +32 50 31 42 69

Fax: +32 50 36 24 17

Email:

Luxembourg/Lu­xemburg

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Penyß^uKa Et.nrapun

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

mene^OH: +44 (0) 20 8447 8899

Email:

Magyarorszag

Dunavet-B ZRt, 7020 Dunaföldvar, Ady E. u. 5. Tel: +36 75 542 940

Email:

Česká republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno

Tel: +42 (0) 54 1426 370

Email:

Malta

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Danmark

Salfarm Danmark A/S

Fabriksvej 21 6000 Kolding

Tel: +45 75 52 94 13

Fax: +45 75 50 80 80

E-mail:

Nederland

Ecuphar BV

Verlengde Poolseweg 16

NL-4818 CL Breda

Tel : +31 (0)88 033 38 00

Fax : +31 (0)88 033 38 11

Email:

Deutschland

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

Norge

Salfarm Scandinavia AB Florettgatan 29C, 2. Vân 25 467 Helsingborg

Sweden

Phone: 0046 767 834 910

Fax: 0045 7550 8080

Email:

Eesti

AS Magnum Veterinaaria Vae 16, Laagri, Harju mk Tel: +372 6 501 920

Fax: +372 6 501 996

Österreich

Ecuphar GmbH Brandteichstrasse 20, 17489 Greifswald, Deutschland,

E-mail: Tel: +49 (0)38348 35840

EXXàôa

DG Nucleus EnE

N.XapÍTOU 11 43100 Kapôiroa

Tql:+302441073034

Email:

Polska

Calier Polska Sp. z o.o. ul. Magazynowa 5, 66–446 Deszczno

Tel: +48 95 7214521 fax: +48 95 7214532

E-mail:

HURTOWNIA LEKOW

WETERYNARYJNYCH „AGA-VET“ ul. Turkowska 58c

62–720 Brudzew

Tel: +48 (63) 279 70 04

Email:

España

Ecuphar Veterinaria S.L.U. Avenida Río de Janeiro, 60–66, planta 13 08016 Barcelona

Tel: +34 (0)935 955 000

Portugal

Belphar LDA

Sintra Business Park No 7, Edificio 1– Escritorio 2K Zona Industrial de Abrunheira 2710–089 Sintra

Tel: +35 (0)13088 08321

France

Laboratoire LCV Z.I. Plessis Beucher 35220 Châteaubourg

Tél : +33 (0)2 99 00 92 92

Fax : +33 (0)2 99 00 97 23

Romania

SC MARAVET SA

Baia Mare

Maravet,

Street No 1

Tel: +40 262 211 964

Email :

Ireland

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenija

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Island

ECO Animal Health Europe Limited 6th Floor, South Bank House Barrow Street

Dublin 4

D04 TR29

IRELAND

Tel: +44 (0) 20 8447 8899

Email:

Slovenská republika

Sevaron s.r.o.

Palackého třída 163a 612 00 Brno Česká Republika

Tel: +42 (0) 54 1426 370

Email:

Italia

Ecuphar Italia S.R.L.

Viale Francesco Restelli, 3/7, piano 1 20124

Milano

Tel: +39 (0)02829 50604

Suomi/Finland

Vetcare Oy

PL 99

24101 Salo

Tel: +358 (0)20 144 3360

Email:

Knnpog

Panchris Feeds (Veterinary) Ltd

Industrial Area Aradippou, 7100, Larnaca,

POB 40261, 6302, Larnaca,

Tql: + 357 24813333

Fax: +357 24813377

Sverige

Salfarm Scandinavia AB Florettgatan 29C, 2. Ván 25 467 Helsingborg Phone: 0046 767 834 9­10 Fax: 0045 7550 808­0 Email:

Latvija

Magnum Veterinarija SIA

Ulbrokas iela 23, Riga, LV-1021

Tel: +371 671 60091

Fax: +371 671 60095

Lietuva

Magnum Veterinarija, UAB

Martinavos g. 8, Martinavos k.,

LT-54463 Kauno r., Lietuva

Tel.: +370 688 96944

Email:

PACKAGE LEAFLET :

Aivlosin 625 mg/g granules for use in drinking water for chickens and turkeys (attached as concertina label directly to the immediate package or as a back label for the 400 g sachet for one language)

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ECO Animal Health Europe Limited

6th Floor, South Bank House

Barrow Street

Dublin 4

D04 TR29

IRELAND

Manufacturer responsible for batch release :

Acme Drugs s.r.l.

Via Portella della Ginestra 9/a

42025 CAVRIAGO (RE)

ITALY

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Aivlosin 625 mg/g granules for use in drinking water for chickens and turkeys Tylvalosin (as tylvalosin tartrate)

3.


STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT

Active substance:

Tylvalosin as tartrate 625 mg/g.

White granules.

4.


INDICATION(S)


Chickens

Treatment and metaphylaxis of respiratory infections caused by Mycoplasma gallisepticum in chickens. The presence of the disease in the flock should be established before metaphylactic treatment.

As an aid in reducing the development of clinical signs and mortality from respiratory disease in flocks, where infection in ovum with Mycoplasma gallisepticum is likely because the disease is known to exist in the parent generation.

Turkeys

Treatment of respiratory disease associated with tylvalosin sensitive strains of Ornithobacterium rhinotracheale in turkeys.

  • 5. CONTRAINDI­CATIONS

None.

  • 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Chickens and turkeys

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For use in drinking water.

Chickens

For treatment of respiratory disease associated with Mycoplasma gallisepticum:

The dose is 25 mg tylvalosin per kg bodyweight per day in drinking water for 3 consecutive days.

When used as an aid in reducing the development of clinical signs and mortality (where infection in ovum with Mycoplasma gallisepticum is likely):

The dose is 25 mg tylvalosin per kg bodyweight per day in drinking water for 3 consecutive days at 1 day old. This is followed by a second treatment with 25 mg tylvalosin per kg bodyweight per day in drinking water for 3 consecutive days at the period of risk, i.e. at times of management stress such as administration of vaccines (typically when birds are 2–3 weeks old).

Determine the combined bodyweight (in kg) of all the chickens to be treated. Select the correct number of sachets according to the amount of product required.

One sachet of 40 g is sufficient for a total of 1,000 kg of chickens (e.g. 20,000 birds with an average bodyweight of 50 g). One sachet of 400 g is sufficient to treat a total of 10,000 kg of chickens (e.g. 20,000 birds with an average bodyweight of 500 g).

In order to achieve a correct dose, the preparation of a concentrated (stock) solution might be required (e.g. to treat a total of 500 kg total bird weight, only 50% of the prepared stock solution prepared from the 40 g sachet should be used).

The product should be added to a volume of water that the chickens will consume in one day. No other source of drinking water should be available during the medication period.

Turkeys

For treatment of respiratory disease associated with tylvalosin-sensitive strains of Ornithobacterium rhinotracheale:

The dose is 25 mg tylvalosin per kg bodyweight per day in drinking water for 5 consecutive days.

Determine the combined bodyweight (in kg) of all the turkeys to be treated. Select the correct number of sachets according to the amount of product required.

One sachet of 40 g is sufficient for a total of 1,000 kg of turkeys (e.g. 10,000 birds with an average bodyweight of 100 g). One sachet of 400 g is sufficient to treat a total of 10,000 kg of turkeys (e.g. 10,000 birds with an average bodyweight of 1 kg).

In order to achieve a correct dose, the preparation of a concentrated (stock) solution might be required (e.g. to treat a total of 500 kg total bird weight, only 50% of the prepared stock solution prepared from the 40 g sachet should be used).

The product should be added to a volume of water that the turkeys will consume in one day. No other source of drinking water should be available during the medication period.

  • 9. ADVICE ON CORRECT ADMINISTRATION

The veterinary medicinal product may be mixed directly into the drinking water system or first mixed as a stock solution into a smaller amount of water, which is then added into the drinking water system.

When mixing the product directly into the drinking water system, the contents of the sachet should be sprinkled onto the surface of the water and mixed thoroughly until a clear solution is produced (usually within 3 minutes).

When preparing a stock solution, the maximum concentration should be 40 g per 1,500 ml or 400 g of product per 15 litres water and it is necessary to mix the solution for 10 minutes. After this time, any remaining cloudiness will not affect the efficacy of the veterinary medicinal product.

Only a sufficient amount of medicated drinking water should be prepared to cover the daily requirements.

Medicated drinking water should be replaced every 24 hours.

WITHDRAWAL PERIOD(S)

Meat and offal: 2 days.

Eggs (chicken): zero days.

Turkeys: Not for use in birds producing or intended to produce eggs for human consumption.

Do not use within 21 days of the start of the laying period.

  • 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

40 g sachet: do not store above 25 °C.

400 g sachet: do not store above 25 °C.

Shelf life after opening the immediate packaging: 5 weeks.

Do not use this veterinary medicinal product after the expiry date, which is stated on the label as “EXP”.

Shelf life of the medicated drinking water: 24 hours.

  • 12. SPECIAL WARNINGS

Special precautions for use in animals:

Good management and hygiene practices should be introduced in order to reduce the risk of reinfection.

Special warnings for each target species

The strategy for Mycoplasma gallisepticum infection should include efforts to eliminate the pathogen from the parent generation.

Infection with Mycoplasma gallisepticum is reduced but not eliminated at the recommended dose.

Medication should only be used for short-term amelioration of clinical signs in breeder flocks whilst awaiting confirmation of diagnosis of Mycoplasma gallisepticum infection.

It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.

Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to potential for cross-resistance.

In field studies investigating the effect of treatment and metaphylaxis on mycoplasmosis, all birds (approximately 3 weeks old) received the product when clinical signs were evident in 2 – 5% of the flock. At 14 days after initiation of treatment, 16.7 – 25.0% morbidity and 0.3 – 3.9% mortality were observed in the treated group in comparison to 50.0 – 53.3% morbidity and 0.3 – 4.5% mortality in an untreated group.

In further field studies, chicks from parent stock with evidence of Mycoplasma gallisepticum infection were administered the product for the first three days of life followed by a second course at 16 – 19 days of age (a period of management stress). By 34 days after the initiation of treatment, 17.5 – 20.0% morbidity and 1.5 – 2.3% mortality were observed in the treated groups in comparison to 50.0 – 53.3% morbidity and 2.5 – 4.8% mortality in the untreated groups.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin should avoid contact with this product.

When mixing the veterinary medicinal product and handling the medicated water, direct contact with eyes, skin and mucous membranes should be avoided. Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a nondisposable respirator conforming to European Standard EN 140 with a filter conforming to European Standard EN 143 should be worn when mixing the product. Wash contaminated skin.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Use during lay:

The safety of the veterinary medicinal product has not been established during lay in turkeys.

The product can be used in chickens laying eggs for human consumption and breeding birds producing eggs for hatching broiler stock or replacement layers.

Overdose (symptoms, emergency procedures, antidotes) :

No signs of intolerance have been observed in poultry species at up to 150 mg tylvalosin per kg bodyweight per day for 5 days.

No adverse effects on egg production, egg fertility, hatchability and chick viability were observed in broiler breeder stock administered 75 mg tylvalosin per kg bodyweight per day for 28 consecutive da­ys.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED <date>